OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hurvitz on the Rationale for the coopERA Breast Cancer Trial in ER+/HER2- Breast Cancer

September 29th 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Weiss on the Efficacy Results of the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

September 29th 2021

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

Dr. Sborov on Managing Bispecific Antibody–Related Adverse Effects in Multiple Myeloma

September 29th 2021

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Dr. Baz on the Utility of Venetoclax in Heavily Pretreated Multiple Myeloma

September 29th 2021

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Dr. Lustberg Discusses Ongoing Research in Breast Cancer

September 28th 2021

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Dr. Backes on Challenges Regarding Staging of Ovarian Germ Cell Tumors

September 28th 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

September 28th 2021

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple Myeloma

September 28th 2021

Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.

Dr. Chi on the Design of the AMPLITUDE Trial in mCSPC

September 28th 2021

Kim Chi, MD, discusses the design of the phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Manasanch on Eligibility for Autologous Transplant in Multiple Myeloma

September 28th 2021

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

September 28th 2021

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

​Dr. Shah on the Potential of Vaccine-Based Therapy in Multiple Myeloma

September 28th 2021

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

Dr. Harris on Remaining Questions With Treatment Sequencing in HCC

September 27th 2021

William P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.

Dr. Popat on Weighing Belantamab Mafodotin–Related Toxicities in Multiple Myeloma

September 27th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi Sarcoma

September 27th 2021

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Dr. Neal on the FDA Approval of Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

September 27th 2021

Joel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Reinmuth on the Rationale for Examining PROs With Tepotinib in METex14-Altered NSCLC

September 27th 2021

Niels Reinmuth, MD, PhD, discusses the rationale for a health utility analysis of tepotinib in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Dr. Cohen on CARTITUDE-2 Data With Cilta-Cel in Multiple Myeloma

September 27th 2021

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Dr. Agarwal on the Design of the AMPLITUDE Trial in mCSPC

September 24th 2021

Neeraj Agarwal, MD, discusses the design of the ongoing phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Cohen on the Shortcomings of Trials Evaluating Cytoreductive Surgery and HIPEC in CRC

September 24th 2021

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

NEXT PAGE
PREVIOUS PAGE